Proliant Biologicals Revenue and Competitors
Estimated Revenue & Valuation
- Proliant Biologicals's estimated annual revenue is currently $7.4M per year.
- Proliant Biologicals's estimated revenue per employee is $155,000
Employee Data
- Proliant Biologicals has 48 Employees.
- Proliant Biologicals grew their employee count by 0% last year.
Proliant Biologicals's People
Name | Title | Email/Phone |
---|
Proliant Biologicals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.9M | 6 | -14% | N/A | N/A |
#2 | $16.1M | 104 | 9% | N/A | N/A |
#3 | $0.8M | 10 | -44% | $2.1M | N/A |
#4 | $504.4M | 2034 | 1% | $31.2M | N/A |
#5 | $8.1M | 52 | 6% | N/A | N/A |
#6 | $2M | 13 | 0% | N/A | N/A |
#7 | $0.3M | 2 | -85% | N/A | N/A |
#8 | $0.2M | 1 | 0% | N/A | N/A |
#9 | $1.8M | 23 | 44% | N/A | N/A |
#10 | $1.4M | 9 | -10% | N/A | N/A |
What Is Proliant Biologicals?
Proliant is the world's largest and most experienced manufacturer of animal-derived proteins, producing a variety of grades of Fraction V Bovine Serum Albumin (BSA). We manufacture BSA in large volumes with the highest level of consistency, traceability & quality available on the market today. We are the only manufacturer of BSA that controls the entire process, from collection, through transport and processing. Proliant is also thrilled to now offer a line of first-class cell culture media component products. With Proliant's history of unmatched excellence, our cell culture media components provides critical elements for industry altering products and the utmost important research. Our media components products currently serve diagnostic, biopharmaceutical and research customers worldwide.
keywords:N/AN/A
Total Funding
48
Number of Employees
$7.4M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $17M | 59 | 5% | N/A |
#2 | $9.6M | 62 | 27% | N/A |
#3 | $23.5M | 81 | 4% | N/A |
#4 | $25.1M | 93 | 6% | N/A |
#5 | $15.3M | 94 | 6% | N/A |